Rafferty Asset Management, LLC Avrobio, Inc. Transaction History

Rafferty Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$5.53 - $9.28 $602,454 - $1.01 Million	-108,943 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$7.84 - $12.6 $78,313 - $125,861	9,989 Added 10.09%	108,943 $969,000
Q1 2021 May 10, 2021	BUY	$10.54 - $19.3 $930,871 - $1.7 Million	88,318 Added 830.37%	98,954 $1.26 Million
Q4 2020 Feb 10, 2021	SELL	$12.79 - $17.1 $209,538 - $280,149	-16,383 Reduced 60.64%	10,636 $148,000
Q3 2020 Nov 13, 2020	BUY	$12.99 - $19.41 $350,976 - $524,438	27,019 New	27,019 $352,000
Q1 2020 May 15, 2020	SELL	$10.08 - $27.21 $128,963 - $348,124	-12,794 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$13.05 - $21.88 $222,894 - $373,710	-17,080 Reduced 57.17%	12,794 $258,000
Q3 2019 Nov 14, 2019	BUY	$14.12 - $23.44 $421,820 - $700,246	29,874 New	29,874 $422,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.